Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

MDS 2020 | Blood transfusion thresholds and QoL in MDS patients

Rena Buckstein • 5 Mar 2020
MDS 2020
Myelodysplastic Syndromes

Rena Buckstein, MD, FRCPC, Odette Cancer Research Program, Sunnybrook Research Institute, Toronto, Canada, discusses the ways in which quality of life (QoL) could be improved in patients receiving blood transfusions. This interview took place at the 2nd Regional Symposium on Myelodysplastic Syndromes (MDS 2020), held in Tel Aviv, Israel.

More from Rena Buckstein

Unmet needs in LR-MDS: RBC transfusion-dependence
2:21
Unmet needs in LR-MDS: RBC transfusion-dependence
Rena Buckstein • 10 Dec 2023
Screening for CHIP to detect potential TMNs in cancer treatment
0:47
Screening for CHIP to detect potential TMNs in cancer treatment
Rena Buckstein • 10 Dec 2023
How our expanding knowledge of pre-malignant conditions may impact clinical decision-making
1:18
How our expanding knowledge of pre-malignant conditions may impact clinical decision-making
Rena Buckstein • 10 Dec 2023
The impact of CHIP on clinical outcomes in older patients with lymphoma undergoing chemotherapy
3:24
The impact of CHIP on clinical outcomes in older patients with lymphoma undergoing chemotherapy
Rena Buckstein • 10 Dec 2023

Related Videos

The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
2:53
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
Rena Buckstein • 6 Dec 2025
Practice-changing highlights in MDS from ASH 2025: the VERONA trial and triplet combinations
1:07
Practice-changing highlights in MDS from ASH 2025: the VERONA trial and triplet combinations
Rena Buckstein • 6 Dec 2025
Outcomes of HMA plus venetoclax in HR-MDS: an analysis from the icMDS validate database
5:58
Outcomes of HMA plus venetoclax in HR-MDS: an analysis from the icMDS validate database
Rena Buckstein • 16 Dec 2025
Olutasidenib with co-targeted therapy in R/R IDH1-mutated myeloid malignancies: Phase II trial
1:30
Olutasidenib with co-targeted therapy in R/R IDH1-mutated myeloid malignancies: Phase II trial
Rena Buckstein • 6 Dec 2025
The content of VJHemOnc is intended for healthcare professionals